We believe that within the next 5 years the treatment of CRPC will continue to evolve. If agents such as MDV3100 and radium-223 are approved by the FDA, we may see them first used in the patients who fail initial therapy and possibly in the chemotherapy-naive setting. The optimal sequencing for abiraterone and sipuleucel-T is yet to be determined, but many believe that if a product such as sipuleucel-T can be given earlier in the disease process, it may be more beneficial. Given the aging population in the USA and the recent push away from PSA screening in the USA, we may very well see an increase in the number of patients who progress to CRPC.
Expert Rev Anticancer Ther. 2012;12(7):951-964. © 2012 Expert Reviews Ltd.